P

Philogen
PHIL

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
€1.09B
EV
€990.81M
Shares Outstanding
40.33M
Beta
0.15

Wall Street View

Analyst Rating
BUY
Analyst Target Price
€29.00
P/E 2025E
4.75x
P/Revenue 2025E
3.45x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Philogen S.p.A.

gainify

P

Philogen S.p.A.

PHIL

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin ...

Sector

Healthcare

Industry

Biotechnology

CEO

Neri, Dario

Employees

183

IPO Date

2021-03-03

Headquarters

Piazza La Lizza #7, Siena, Siena, 53100, Italy

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.